Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Peking University

Headquarters: Beijing, China
Year Founded: 1898
Status: Non-biopharma

Biopharma related deals can be found by searching the organization's name in the Deals Module.

BioCentury | Aug 8, 2024
Discovery & Translation

Science Spotlight: Stopping herpes from entering neurons, tissue-specific nanoparticles, and more

BioCentury’s roundup of translational innovations
BioCentury | Jun 6, 2024
Discovery & Translation

Science Spotlight: Engineered CD47 protects CAR T cells from macrophages and more

BioCentury’s roundup of translational innovations
BioCentury | May 31, 2024
Distillery Therapeutics

Targeting a GLP-1R-agmatine axis for PCOS

BioCentury | May 11, 2024
Discovery & Translation

Science spotlight: An antidote to reverse anticoagulants, two ocular gene therapies, and more

BioCentury’s roundup of translational innovations
BioCentury | Nov 2, 2023
Distillery Therapeutics

A synthetic GPR132 antagonist for Type II diabetes

BioCentury | Sep 15, 2023
Discovery & Translation

Mini Cas protein iterations; plus Moderna’s Lassa virus vaccine and more

BioCentury’s roundup of translational innovations
BioCentury | Aug 29, 2023
Distillery Therapeutics

Microbial DPP-4 inhibitor for Type II diabetes

BioCentury | Aug 17, 2023
Product Development

Emerging circular RNA field split on what to deliver and how to deliver it

The rising therapeutic modality is more durable than linear mRNA, promising efficacy and manufacturing advantages
BioCentury | Aug 2, 2023
Distillery Therapeutics

Inhibiting a circular RNA-encoded MET variant for glioblastoma

Items per page:
1 - 10 of 103
Help Center
Username
Request a Demo
Request Training
Ask a Question